Skip to main content
TipRanks
Go Ultimate75% OFF

Royalty Pharma (RPD) Stock Statistics & Valuation Metrics

6 Followers

Total Valuation

Royalty Pharma has a market cap or net worth of EUR 35.76B. The enterprise value is EUR 43.51B.

Market Cap
EUR 35.76B
Enterprise Value
EUR 43.51B

Share Statistics

Royalty Pharma has 445,265,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
445,265,800
Owned by Insiders
1.57%
Owned by Institutions
66.43%

Financial Efficiency

Royalty Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.95%.

Return on Equity (ROE)
0.12
Return on Assets (ROA)
0.04
Return on Invested Capital (ROIC)
8.95%
Return on Capital Employed (ROCE)
0.08
Revenue Per Employee
23.78M
Profits Per Employee
7.71M
Employee Count
100
Asset Turnover
0.12
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Royalty Pharma is 41.04. Royalty Pharma’s PEG ratio is -1.81.

PE Ratio
41.04
PS Ratio
11.66
PB Ratio
4.47
Price to FCF
10.31
Price to Operating Cash Flow
10.33
PEG Ratio
-1.81

Income Statement

In the last 12 months, Royalty Pharma had revenue of 2.38B and earned 770.95M in profits. Earnings per share was 2.33.

Revenue
2.38B
Gross Profit
2.38B
Operating Income
1.56B
Pretax Income
1.32B
Net Income
770.95M
EBITDA
1.64B
Earnings Per Share (EPS)
2.33

Cash Flow

In the last 12 months, operating cash flow was 2.96B and capital expenditures 0, giving a free cash flow of 2.96B billion.

Operating Cash Flow
2.96B
Free Cash Flow
2.96B
Free Cash Flow per Share
6.64

Dividends & Yields

Royalty Pharma pays an annual dividend of ―, resulting in a dividend yield of 1.35%

Dividend Per Share
―
Dividend Yield
1.35%
Payout Ratio
N/A
Free Cash Flow Yield
9.70%
Earnings Yield
2.20%

Stock Price Statistics

Beta
0.32
52-Week Price Change
90.51%
50-Day Moving Average
54.19
200-Day Moving Average
46.95
Relative Strength Index (RSI)
76.44
Average Volume (3m)
68

Important Dates

Royalty Pharma upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 04, 2026
Next Earnings Date
Feb 16, 2027
Ex-Dividend Date
―

Financial Position

Royalty Pharma as a current ratio of 0.97, with Debt / Equity ratio of 138.20%

Current Ratio
0.97
Quick Ratio
0.97
Debt to Market Cap
0.54
Net Debt to EBITDA
5.09
Interest Coverage Ratio
5.07

Taxes

In the past 12 months, Royalty Pharma has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Royalty Pharma EV to EBITDA ratio is 25.11, with an EV/FCF ratio of 13.04.

EV to Sales
14.75
EV to EBITDA
25.11
EV to Free Cash Flow
13.04
EV to Operating Cash Flow
13.04

Balance Sheet

Royalty Pharma has EUR 544.86M in cash and marketable securities with EUR 8.59B in debt, giving a net cash position of -EUR 8.04B billion.

Cash & Marketable Securities
EUR 544.86M
Total Debt
EUR 8.59B
Net Cash
-EUR 8.04B
Net Cash Per Share
-EUR 18.06
Tangible Book Value Per Share
EUR 19.89

Margins

Gross margin is 89.75%, with operating margin of 57.14%, and net profit margin of 25.66%.

Gross Margin
89.75%
Operating Margin
57.14%
Pretax Margin
44.80%
Net Profit Margin
25.66%
EBITDA Margin
58.71%
EBIT Margin
58.57%

Analyst Forecast

The average price target for Royalty Pharma is EUR 63.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
EUR 63.88
Price Target Upside
1.94% Upside
Analyst Consensus
Strong Buy
Analyst Count
6
Revenue Growth Forecast
5.84%
EPS Growth Forecast
-16.96%

Scores

Smart Score
10
AI Score
―